Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol-Myers Squibb Co BMY
News
Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Leveraging Brazil's Health Networks for Early Lung Cancer Detection
Transforming Lung Cancer Care & Early Detection in Tanzania
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
How Can Lung Cancer Screening in India Reflect Risk Beyond Smoking?
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Bristol Myers Squibb Announces Dividend
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Bristol Myers Squibb Gets FDA Approval for Myeloma Treatment
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Cytokinetics Files Complaint on Patent Issue Against Bristol-Myers Squibb
United States